Could a tiny ear device replace opioids after cancer surgery?
NCT ID NCT05742711
First seen Jun 26, 2026 ยท Last updated Jun 26, 2026
Summary
This study tested a device that sends mild electrical pulses to the ear (called PENS) to see if it can reduce pain and the need for strong painkillers after surgery for endometrial or cervical cancer. 48 women who had open surgery took part. The goal was to find a safer, non-drug way to manage pain without the side effects of opioids.
What this could mean
Our plain-language read of the trial. This is informational only โ not medical advice or a prediction.
- Active substance
- Percutaneous Electrical Nerve Stimulator (PENS) device
- What this could lead to
- If it works, this could offer a non-drug way to manage pain after cancer surgery, reducing the need for opioids and their side effects.
- What could go wrong
- This is a small, completed trial with only 48 people. The device may not work better than a sham device, and results may not apply to all surgeries or cancers.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER OF CERVIX are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cancer Institute,(Wia)
Chennai, Tamil Nadu, 600020, India
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Protein clues may predict cervical cancer return
- Zimbabwe study targets cancer prevention with vaccines and mental health care
- New hope for aggressive uterine cancer: vaccine and drug combo trial launches
- Magic mushroom therapy targets Cancer-Related anxiety in new trial
- AI aims to revolutionize cancer trial enrollment for 50,000 patients